Discover
MRSN
Mersana Therapeutics, Inc.
29.08
2 x 20.63
2 x 36.80
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
29.36 +0.28 (0.96%)
| Ytd | 0.52% | |
| 1y | -14.47% |
28.78
day range
30.36
52 week range
| Open | 28.78 | Prev Close | 29.08 | Low | 28.78 | High | 30.36 | Mkt Cap | N/A |
| Vol | 704.86K | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -2.19 |
| Beta | 1.48 | Short Ratio | 6.45 | Inst. Own | 95.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 6.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.18 | -0.09 | 0.09 | 50.00% |
| 2024-08-13 | 2024-06 | -0.18 | -0.2 | -0.02 | -11.11% |
| 2024-05-09 | 2024-03 | -0.18 | -0.16 | 0.02 | 11.11% |
| 2024-02-28 | 2023-12 | -0.2 | -0.16 | 0.04 | 20.00% |
| 2023-11-07 | 2023-09 | -0.31 | -0.35 | -0.04 | -12.90% |
| 2023-08-08 | 2023-06 | -0.39 | -0.47 | -0.08 | -20.51% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-27 | Citigroup | Upgrade | Buy | Buy |
| 2024-08-14 | Baird | Upgrade | Neutral | Neutral |
| 2024-03-19 | JP Morgan | Upgrade | Underweight | Neutral |
| 2024-02-29 | Wedbush | Upgrade | Neutral | Outperform |
| 2024-02-29 | Truist Securities | Upgrade | Hold | Buy |
| 2024-02-29 | Baird | Upgrade | Neutral | Neutral |
Profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-27 | BALA MOHAN | Officer | 54.73K | Sale |
| 2024-10-02 | CARVAJAL ALEJANDRA V. | Officer | 63.72K | Sale |
| 2024-01-01 | DERE WILLARD H | Director | 39.18K | Stock Award(Grant) |
| 2024-10-02 | DESCHUYTNER BRIAN | Chief Operating Officer | 94.82K | Sale |
| 2024-09-11 | HUBER MARTIN H JR | Chief Executive Officer | 116.33K | Sale |
| 2024-10-02 | LOWINGER TIMOTHY B | Chief Technology Officer | 235.64K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | EcoR1 Capital, LLC | 19.36M | 29.63M | 15.68% |
| 2024-09-29 | Nextech Invest Ag | 12.07M | 18.46M | 9.77% |
| 2024-09-29 | VR Adviser, LLC | 11.33M | 17.33M | 9.17% |
| 2024-09-29 | Bain Capital Life Sciences Investors, LLC | 8.66M | 13.26M | 7.01% |
| 2024-09-29 | Blackrock Inc. | 8.62M | 13.19M | 6.98% |
| 2024-09-29 | Vanguard Group Inc | 7.18M | 10.98M | 5.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 3.47M | 5.31M | 2.81% |
| 2024-10-30 | iShares Russell 2000 ETF | 2.97M | 4.54M | 2.40% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.52M | 2.33M | 1.23% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 1.18M | 1.81M | 0.96% |
| 2024-07-30 | Vanguard Explorer Fund, Inc. | 614.97K | 940.91K | 0.50% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 539.00K | 824.66K | 0.44% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2025-07-28 |